While patients with estrogen receptor (ER-positive) and human epidermal growth factor receptor 2 (HER2-positive) BC benefit from targeted therapies, treatment options for women with triple-negative breast cancer (TNBC) have changed little over the last few decades. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.